Zoetis Inc. (ZTS) Revenue History
Annual and quarterly revenue from 2010 to present
ZTS Revenue Over Time (2010–2025)
ZTS Revenue Growth History
14 of 15 years with positive growth- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- +18.2%
- FY2012 revenue growth
- +2.4%
- FY2013 revenue growth
- +5.2%
- FY2014 revenue growth
- +4.9%
- FY2015 revenue growth
- -0.4%
- FY2016 revenue growth
- +2.6%
- FY2017 revenue growth
- +8.6%
- FY2018 revenue growth
- +9.8%
- FY2019 revenue growth
- +7.5%
- FY2020 revenue growth
- +6.6%
- FY2021 revenue growth
- +16.5%
- FY2022 revenue growth
- +3.9%
- FY2023 revenue growth
- +5.7%
- FY2024 revenue growth
- +8.3%
- FY2025 revenue growth
- +2.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.26B | +1.9% |
| Q4 2025 | $2.39B | +3.0% |
| Q3 2025 | $2.40B | +0.5% |
| Q2 2025 | $2.46B | +4.2% |
| Q1 2025 | $2.22B | +1.4% |
| Q4 2024 | $2.32B | +4.7% |
| Q3 2024 | $2.39B | +11.0% |
| Q2 2024 | $2.36B | +8.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ZTS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ZTS Revenue Analysis (2010–2025)
Current Revenue & Growth
As of June 21, 2026, Zoetis Inc. (ZTS) generated trailing twelve-month (TTM) revenue of $9.51 billion, reflecting modest growth of +1.9% year-over-year. The most recent quarter (Q1 2026) recorded $2.26 billion in revenue, down 5.2% sequentially.
Historical Growth Trajectory
ZTS's 5-year compound annual growth rate (CAGR) stands at +7.2%, indicating steady revenue expansion. The 3-year CAGR of +5.4% is below the 5-year average, signalling a growth deceleration in recent years. Zoetis Inc.'s highest annual revenue of $9.47 billion was recorded in 2025, an all-time high.
Revenue by Segment
ZTS's revenue is primarily driven by Horses (68%), Cattle (16%), and Swine (5%). With over half of revenue concentrated in Horses, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ELAN (+10.5% YoY), PCRX (+4.6% YoY), and PAHC (+32.4% YoY) — ZTS has underperformed the peer group in revenue growth. Compare ZTS vs ELAN →
ZTS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZTSCurrent | $9.5B | +1.9% | +7.2% | 38.0% | |
 ELAN | $4.7B | +10.5% | +7.6% | 5.3% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% |
ZTS Historical Revenue Data (2010–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.47B | +2.3% | $6.67B | 70.5% | $3.60B | 38.0% |
| 2024 | $9.26B | +8.3% | $6.40B | 69.1% | $3.39B | 36.6% |
| 2023 | $8.54B | +5.7% | $5.83B | 68.3% | $3.07B | 35.9% |
| 2022 | $8.08B | +3.9% | $5.48B | 67.8% | $2.93B | 36.2% |
| 2021 | $7.78B | +16.5% | $5.31B | 68.3% | $2.80B | 36.0% |
| 2020 | $6.67B | +6.6% | $4.46B | 66.8% | $2.27B | 34.0% |
| 2019 | $6.26B | +7.5% | $4.11B | 65.7% | $2.02B | 32.2% |
| 2018 | $5.83B | +9.8% | $3.80B | 65.2% | $1.88B | 32.3% |
| 2017 | $5.31B | +8.6% | $3.44B | 64.9% | $1.73B | 32.5% |
| 2016 | $4.89B | +2.6% | $3.14B | 64.3% | $1.40B | 28.7% |
| 2015 | $4.76B | -0.4% | $2.97B | 62.3% | $1.08B | 22.7% |
| 2014 | $4.79B | +4.9% | $3.01B | 62.9% | $970.0M | 20.3% |
| 2013 | $4.56B | +5.2% | $2.83B | 62.1% | $821.0M | 18.0% |
| 2012 | $4.34B | +2.4% | $2.72B | 62.7% | $854.0M | 19.7% |
| 2011 | $4.23B | +18.2% | $2.54B | 60.0% | $684.0M | 16.2% |
Full Stock Analysis
Deep dive into ZTS consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZTS — Frequently Asked Questions
Quick answers to the most common questions about buying ZTS stock.
Is ZTS's revenue growth accelerating or slowing?
ZTS revenue growth is slowing. TTM revenue is $9.5B, up +1.9% year-over-year — below the 5-year CAGR of +7.2%. The deceleration suggests maturing end-markets or increased competition.
What is ZTS's revenue history from 2010 to 2026?
Zoetis Inc. (ZTS) revenue history spans 2010 to 2026. TTM revenue as of 2026 is $9.5B, growing at +1.9% YoY. The 5-year CAGR is +7.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ZTS's long-term revenue growth rate (CAGR)?
Zoetis Inc.'s 5-year revenue CAGR of +7.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +1.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ZTS.
Why does ZTS's quarterly revenue fluctuate?
ZTS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Zoetis Inc.'s revenue data from 2010 to 2026 shows full historical quarterly detail on this page.
How is ZTS's revenue distributed by segment?
ZTS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ZTS's revenue compare to industry peers?
Zoetis Inc. (ZTS) with TTM revenue of $9.5B and +1.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.